China-based Brii Biosciences Limited (HKG: 2137) announced the exercise of its option to acquire exclusive development and commercialization rights for VIR-3434 (BRII-877) in Greater China as part of its broader collaboration with Vir Biotechnology, Inc. (NASDAQ: VIR).
Drug Profile
VIR-3434, an investigational subcutaneously administered HBV-neutralizing monoclonal antibody, is designed to block the entry of all 10 genotypes of HBV into hepatocytes and reduce the level of virions and subviral particles in the blood. The drug is currently in Phase II development. This acquisition adds to Brii Bio’s leading clinical pipeline for hepatitis B virus (HBV) and provides potential combination treatment options aimed at developing a functional cure for HBV.
Collaboration Background
In May 2018, Brii Bio entered into a collaboration, option, and license agreement with Vir, granting Brii Bio the option to acquire exclusive rights to certain Vir programs in Greater China. In June 2020, Brii Bio exercised its option for BRII-835 (VIR-2218). Under the current agreement, Brii Bio will pay an option exercise fee, regulatory and commercial milestone payments, and tiered royalty payments based on net sales for VIR-3434 (BRII-877). The company retains two pending licensing options.-Fineline Info & Tech
